Work

Abstract LB-193: Preclinical antitumor activity of a first-in-class TREM-1 inhibitory peptide GF9 as monotherapy and in combo with chemotherapy or radiation

Year: 2019

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2019-lb-193

Authors: Daniel J. Mark, Zu T. Shen, Rosamaria Ruggieri, Marc H. Symons, Alexander B. Sigalov

Institutions: Northwell Health, SignaBlok (United States)

Language: English

Topic: Inflammation biomarkers and pathways

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2954891905

Cites:

Cited by:

Related to: 10